Phenotypic diversity drives paracrine drug tolerance by Thomas Kuilman, Daniel S Peeper

Get full text

TRAF2 and RIPK1 redundantly mediate classical NFκB signaling by TNFR1 and CD95-type death receptors by Jennifer Wagner, David Vredevoogd, Xin Yu, Dong Lu, Daniel S. Peeper, Heike M. Hermanns, Jin Wang, Harald Wajant, Daniela Siegmund

Get full text

ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma by Marjon A Smit, Gianluca Maddalo, Kylie Greig, Linsey M Raaijmakers, Patricia A Possik, Bas van Breukelen, Salvatore Cappadona, Albert JR Heck, AF Maarten Altelaar, Daniel S Peeper

Get full text

Resistance to BRAF inhibitors drives melanoma sensitivity to Chk1 inhibition by Danielle G. Carvalho, Juliana C.N. Kenski, Daniel A. Moreira, Matheus A. Rajão, Oscar Krijgsman, Carolina Furtado, Mariana Boroni, João P.B. Viola, Daniel S. Peeper, Patricia A. Possik

Get full text

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors by Alireza Azimi, Stefano Caramuta, Brinton Seashore‐Ludlow, Johan Boström, Jonathan L Robinson, Fredrik Edfors, Rainer Tuominen, Kristel Kemper, Oscar Krijgsman, Daniel S Peeper, Jens Nielsen, Johan Hansson, Suzanne Egyhazi Brage, Mikael Altun, Mathias Uhlen, Gianluca Maddalo

Get full text

TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction by Gal Markel, Michal J Besser, Eytan Ruppin, Oscar Krijgsman, Daniel S Peeper, Judit Díaz-Gómez, Ettai Markovits, David W Vredevoogd, Georgi Apriamashvili, Pierre L Levy, Sanju Sinha, Zowi R Huinen, Nils L Visser, Beaunelle de Bruijn, Julia Boshuizen, Susan E van Hal-van Veen, Maarten A Ligtenberg, Onno B Bleijerveld, Chun-Pu Lin, Santiago Duro Sánchez, Juan Simon Nieto, Alex van Vliet, Maarten Altelaar

Get full text